Gel Med Sciences (Gel Med) is a privately owned, specialty pharmaceutical company supported by angel and venture capital. The Company is developing animal and human healthcare products utilizing its proprietary Gel Drug Delivery System (GDDS). The GDDS is a novel transmucosal drug delivery method for systemic and/or local delivery of drugs that heretofore could only be delivered by injection. Gel Med's lead animal reproduction product is being funded by and co-developed with a corporate partner in the Animal Science Industry. Gel Med's plans to file its first Investigational New Drug Application (IND) in 2006 for its lead human healthcare product to treat infertility. Gel Med operates as a "virtual" company with management focused on advancing its technology and products using external service providers and academic and corporate partners for all development studies, allowing for a cost-effective, rapid and flexible development process. Gel Med is seeking additional co-development partnerships to develop a broader range of products that can benefit from the GDDS.
Bio-Technology General Corp. was founded in 1980 to develop, manufacture and market novel therapeutic products The Company’s overall administration, licensing, human clinical studies, marketing activities, quality assurance and regulatory affairs are primarily coordinated at the Company’s headquarters in Iselin, New Jersey Pre-clinical studies, research and development activities and manufacturing of the Company’s biotechnology derived products are primarily carried out through Bio-Technology General (Israel) Ltd. ("BTG-Israel"), the Company’s wholly-owned subsidiary, in a 94,000 square foot facility in Rehovot, Israel which is GLP and GMP compliant. As of February 1, 1999 the Company had 271 employees, most of whom are engaged in research, development, manufacturing, quality assurance and marketing activities, including 36 who hold Ph.D. or M.D. degrees The Company’s research and development organization comprises 79 scientists, associates and related personnel with expertise in molecular biology, cell biology and protein chemistry These individuals have received various undergraduate and advanced degrees at prestigious universities throughout the world In addition, the Company has consulting arrangements with scientists at various institutions and universities in the United States and Israel.
CBA Pharma, Inc. is a specialty pharmaceutical company headquartered in Lexington, Kentucky. CBA Pharma, Inc. is organized to exclusively manufacture, market, license and distribute to the medical oncology community a drug, CBT-1Ô, developed to be an effective treatment for cancer that has developed or may develop drug resistance to chemotherapy. Multiple Drug Resistance (MDR) is the phenomenon whereby cells become resistant to a variety of chemotherapy drugs. Resistance of cancer cells to chemotherapy remains the major cause of treatment failure.
Burren Pharmaceuticals, Inc. is a privately held niche pharmaceutical company engaged in the acquisition and development of products in under-served markets. Burren is focused on the treatment of gastrointestinal diseases. The Company's strategy is to acquire drug candidates which have been orphaned by other pharmaceutical companies and employ sophisticated cost effective commercialization strategies to enhance the value of the products.
Conatus Pharmaceuticals was founded by the executive management team of Idun Pharmaceuticals in July 2005 following the successful sale of Idun to Pfizer. At Idun, the Conatus team pioneered the science of apoptosis and the clinical development of pan caspase inhibitors, validating this first-in-class technology. Conatus has well established relationships with key opinion leaders in the fields of hepatology, infectious disease and inflammation. The Conatus team has over 80 years of experience in the pharmaceutical industry and has created multiple successful partnerships with global pharmaceutical companies. The Conatus team has an excellent track record with blue chip investors that are active in financing successful biotechnology companies. We are building our portfolio in the areas of inflammation and liver disease, including infectious and metabolic diseases. Conatus is a privately held company based in San Diego, California.
http://www.azayatherapeutics.com
Azaya Therapeutics, Inc. is an emerging specialty pharmaceutical company with a novel drug delivery system. Its proprietary Protein Stabilized Nanoparticle (PSNÔ) technology platform addresses the significant problems associated with delivery of water insoluble drugs. The Company is initially applying its PSN technology to produce a targeted, safer and more efficacious formulation of a marketed chemotherapy drug for the treatment of cancer. During the late 70's and early 80's liposomes were reengineered to circulate longer in the blood and remain intact while doing so. This was done first by grafting the liposome with glycolipids, followed by a second generation and more robust grafting of the liposome with methoxypolyethylene glycol (mPEG), otherwise referred to as stealth liposomes. The PEG grafted liposomes increased the in vivo liposome stability, reduced MPS uptake and provided longer plasma residence times. In short, the liposome was engineered for use in the pharmaceutical industry, but still remand difficult to produce on large scale for production. As a result, Azaya Therapeutics has developed its Protein Stabilized Nanoparticle (PSNÔ) technology that utilizes a one step manufacturing process. The liposome product is prepared in a single step that encapsulates the active drug ingredient in the lipid layer of the liposome while forming active nanoparticles in situ (60,80 nm). Although many of the known cyctotoxic agents are poorly soluble, Azaya's PSN technology offers a potential solution that not only addresses formulation issues of poorly soluble compounds; it can also enhance the activity (efficacy) of known drug products through targeting mechanisms. Azaya's single step manufacturing process incorporates key characteristics that enhance existing liposomal technology for drug delivery. To date, there have been only moderate advances and Azaya's PSN technology is a large step towards a more efficient and economical drug delivery system. Additionally, standardized manufacturing produces uniform particles that are necessary for passive targeting of cancer tumors via the EPR effect. In addition, Azaya Therapeutics PSNÔ proprietary technology targets the over expression of key proteins that are found in tumor cells. With this superior technology, Azaya Therapeutics has conducted pre-clinical studies that have demonstrated improved therapeutic potential; enhanced pharmacokinetics, enhanced inhibition of tumor xenograft models, and evidence of increased tumor uptake of active compound. Azaya is looking to partner with companies by offering an effective proprietary process to extend marketing life of existing or new development products by enhancing therapeutic performance. Azaya's initial product focus is to apply its PSN technology to currently approved drugs, such as Taxotere (docetaxel), in order to increase the probability of regulatory approval and reduce the associated risk and cost of development. Azaya's lead product candidate ATI-1123 (PSNÔ docetaxel) has demonstrated in preclinical studies superior pharmacokinetics and efficacy compared to Taxotere. Process development and implementation of GLP toxicology studies has been initiated. Alternatively, a secondary product candidate ATI-1150 (PSN SN-38) is currently being evaluated in confirmatory preclinical studies.
QRxPharma Ltd is a clinical-stage specialty pharmaceutical company focused on the development and commercialization of therapies for pain management and central nervous system (CNS) disorders. The Company’s product portfolio includes both late and early stage clinical drug candidates with well defined paths to regulatory approval and sales. QRxPharma’s lead compound, Q8003IR, completed initial Phase III studies in April 2008, having met all primary and secondary endpoints. The Company’s preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. The Company's wholly owned subsidiaries include The Lynx Project Pty Limited, Haempatch Pty Limited and QRx Pharma, Inc. (Source: ARS)
Swiss Medica, Inc. is a specialty pharmaceutical company focused on over-the-counter (OTC), clinically tested, all-natural products that relieve chronic ailments. The Company is engaged in the business of marketing and distributing bioscience health products, with the focus on chronic ailments. Swiss Medica's product is an all-natural essential oil product line called O24 Pain Neutralizer (O24) and has been medically proven to provide temporary relief for minor pains associated with arthritis, backaches and other chronic pains. Swiss Medica commercializes clinically tested, all-natural, OTC products that relieve chronic ailments, including pain and premenstrual syndrome. (Source: 10KSB)
http://www.pilottherapeutics.com
Pilot utilizes scientific innovation and clinical testing approaches to produce a pipeline of human and veterinary medical food products aimed at huge markets and capable of rapidly moving into the marketplace. Through these approaches, Pilot has created a robust pipeline of medical food products for inflammatory diseases such as asthma, allergies, arthritis, diabetes, and heart disease in humans and animals. The company leverages its extensive market-led innovation expertise to take high potential technologies from concept to validated product platform with full understanding of the consumer experience, differentiating benefits, product, packaging, regulatory approach and supply chain. The company primarily looks to bring these validated product platforms to the U.S. and global markets through strategic partnerships with well-positioned market leaders seeking to establish new, innovative growth platforms. Pilot's first medical food product is a proprietary fatty acid combination for the dietary management of allergies and asthma. This product was developed and tested by Pilot in five clinical trials to validate safety and efficacy and licensed to Efficas, a Colorado-based consumer focused health-science and technology company (http://www.efficas.com).
Enhance Biotech Inc. is developing a product portfolio focused upon two key areas of lifestyle drug development; Male Sexual Dysfunction and clinical Skincare indications. Key conditions within the Sexual Dysfunction area include Premature Ejaculation and Male Fertility, while Skincare Indications include Periodontal Disease, Cellulite, Anti-aging and Dermatological Disorders such as Atopic Dermatitis to Psoriasis. Enhance's products are licensed in at pre-clinical or Phase I stages and are being taken through development and approval to market mainly through targeted licensing partnerships for each product, adding significant value to each in the process. This creates a valuable product portfolio in the lifestyle market; a market forecast at conservative estimates to grow to US$32 billion by 2008. The pharmaceutical industry has invested over $20 billion in R&D for lifestyle drugs over the last ten years, although relatively few new products have as yet reached the market. Enhance's lead development products fill unmet needs in these global blockbuster markets. The Management and Science Team have a proven track record of successful new product development and commercialization as well as intellectual property out-licensing.
http://www.alteatherapeutics.com
Altea Therapeutics is an emerging specialty pharmaceutical company developing and commercializing products based on a new transdermal patch technology that can deliver therapeutic levels of water-soluble small drugs, therapeutic proteins, carbohydrates, and vaccines through the skin in a convenient, painless and cost-effective manner. Altea Therapeutics has demonstrated in several clinical studies that its patented PassPort Transdermal System achieves what existing transdermal patches are unable to do, namely the delivery through the skin of compounds that are typically administered by needle injections. The company is currently conducting clinical trials in the United States for its products, which include a Transdermal Basal Insulin Patch designed to provide continuous delivery of insulin for people with Type 1 and Type 2 diabetes and a Transdermal Fentanyl Citrate Patch that enables rapid and safe management of moderate to severe pain. Furthermore, the company is in clinical and pre-clinical development with a number of product candidates, including an undisclosed transdermal protein patch, a parathyroid hormone analog transdermal patch for osteoporosis, and an atypical antipsychotic transdermal patch for the management of psychosis. Altea Therapeutics is the recipient of the Frost & Sullivan 2007 Technology Innovation Award for its development of the PassPort System.
MediQuest Therapeutics is a privately held specialty pharmaceutical company headquartered in Bothell, Washington. MediQuest is a specialty pharmaceutical company developing first- and best- in-class topical therapies to treat patients suffering from inflammatory and infectious diseases. Using a proprietary drug delivery technology, MediQuest can deliver a topical therapy through thickened or diseased skin and nails. The Company's innovative treatment approach and proprietary drug delivery system have generated a robust late-stage clinical pipeline aimed at treating inflammatory/infectious diseases and satisfying unmet medical needs. For information about Raynauds, visit www.mqti.com/raynauds.
About The BioBalance Corporation BioBalance, a development stage specialty pharmaceutical company, is focused on the development of patented biotherapeutic agents for gastrointestinal disorders that are poorly addressed by current therapies via accelerated regulatory pathways. These disorders include pouchitis, Irritable Bowel Syndrome (IBS), inflammatory bowel disease and diarrhea caused by antibiotics, chemotherapy or AIDS. On January 2, 2003, New York Health Care and BioBalance completed a business combination accounted for as a "reverse acquisition," in which BioBalance became a wholly owned subsidiary of the Company. The Company's common stock trades on the OTC Bulletin Board under the symbol BBAL.
Elan Pharmaceuticals, Inc. is a wholly-owned subsidiary of Elan Corporation, plc (NYSE: ELAN). Elan is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges.
Vernalis is a UK-based specialty pharmaceutical company with two marketed products, Apokyn® to treat immobilising "off" episodes in patients with advanced Parkinson's disease and Frova®, to treat migraine. The company has a broad development pipeline focused on neurology and central nervous system disorders.
Neurochem's strategic plan focuses on the research, development and commercialization of products to provide innovation health solutions to patients suffering from serious diseases. With promising drug candidates currently in clinical trials and with expanding drug development programs, Neurochem is a company coming of age. The Company was founded in 1993 by the technology transfer office of Queen's University, Parteq Research and Development Innovations, in Kingston, Ontario, Canada, to develop and commercialize small organic molecules. These molecules, discovered by lead researchers at the university, form the basis of Neurochem's unique technology. Today, Neurochem is proud to count on the dedication of a team of close to 200 researchers, management and staff. To advance the development of its breakthrough technologies through clinical trial and commercialization phases, Neurochem has entered and continues to negotiate a variety of international R&D agreements, partnerships, collaborations and contracts with renowned scientists, researchers, academic institutions, pharmaceutical companies and contract research organizations, while maintaining the full ownership of its therapeutic rights. Our site is best viewed with IE4+ at a resolution of 1024×768.
AlphaRx is developing several drug products in the therapeutic categories of Osteoarthritis and Infectious Disease. AlphaRx intends to file IND and NDA submissions with the FDA (when necessary) and license these products to other pharmaceutical companies for worldwide commercialization. The following is a list of AlphaRx's Pharmaceutical Products in the pipeline: Name Indication Delivery Route Stage Indaflex Ô Osteoarthritis Topical Phase II Streptomycin NDS Ô Tuberculosis Oral Preclinical Zysolin Ô Infection Parenteral Preclinical
Actelion Ltd is a Swiss biopharmaceutical company that focuses on the discovery and development of treatments to serve unmet medical needs. Its products specialize in conditions related to the endothelium. The Company has three approved drugs on the market. Tracleer, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension, a chronic, life-threatening disorder that severely compromises the functions of the lungs and heart. Ventavis is an inhaled formulation of iloprost, a synthetic analogue of prostacyclin PGI2 that dilates systemic and pulmonary arterial vascular beds. It also affects platelet aggregation. The third drug, Zavesca, was in-licensed from Oxford GlycoSciences. Zavesca is an approved oral treatment for type 1 Gaucher disease, a rare debilitating metabolic disorder. In addition, the Company was evaluating nine compounds in various phases of clinical development in 2007.
At ILEX, we continue to research and acquire compounds with unique mechanisms of action, targeting novel receptors. We are focused on building a portfolio of oncology compounds that are different than those already available to patients and that provide new hope with effective and safe treatments for cancer. The ILEX history of drug development remains the core competency of the company and is now focused on ILEX's own pipeline. In addition to its strong scientific and clinical staff, ILEX has a knowledgeable management team with extensive pharmaceutical industry experience. ILEX is building a product-driven biopharmaceutical company focused primarily in oncology. ILEX has a marketed product, CAMPATH® (alemtuzumab) in the United States and MABCAMPATH® in the European Union, and is advancing an innovative and diversified pipeline of compounds.
Aspreva is focused on addressing the needs of individuals with less common diseases through the identification, development and commercialization of existing medicines for new indications. Aspreva uses a proprietary screening program to identify late stage and approved medicines that show potential for high therapeutic impact in less common diseases. We then partner with pharmaceutical and biopharmaceutical companies to acquire the rights to develop the drug in these new indications, including clinical research and regulatory approvals. Once approved, we apply a strategic and specialized approach to commercializing products for these complex therapeutic categories. Our expertise lies in the clinical, regulatory and commercial development of products for complex diseases and specialized patient populations which differs significantly from traditional pharmaceutical activities. Aspreva is a leader in this new era of pharmaceutical partnering.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory